Pay in 4 interest-free payments of $6.09 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
New therapeutic target expands options for multiple myeloma In a Phase I clinical trial, the investigational bispecific antibody cevostamab reduced cancer in more than 40 percent of patients with multiple myeloma.
Health (2019)
Studies in disease-free individuals show inconsistent results
This combination addresses both the caloric and hormonal sides of weight management
It was carried out at 50 outpatient clinics in nine countries across Asia, Europe, and North America
Mental health effects were not a primary endpoint in these studies, though adverse event reporting captured some psychiatric symptoms
US$ 24.70
US$ 20.12
US$ 22.60
US$ 26.23
US$ 27.51
US$ 22.74
US$ 24.74
US$ 25.82
